NCT05261126: A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)
- State
- Completed
- Phase
- Phase 2
- People
- 381 taking part
- Started
- 10 Mar 2022
- Primary completion
- 28 Nov 2022
- Arms
- Enclitide Chloride 6 mg, Enclitide Chloride 12 mg, Enclitide Chloride 18 mg, Enclitide Chloride 30 mg
- Results
- Posted on the registry
- 2 Mar 2022: Trial registered
- 10 Mar 2022: Trial started
- 28 Nov 2022: Trial completed
- 6 Dec 2023: Trial results posted